Ranitidine recall impacts Dr Reddy's P&L by Rs 40-crore

Dr Reddy's Laboratories which initiated a voluntary recall of its Ranitidine at the retail level for over-the-counter products and at the consumer level sold in the US due to confirmed contamination with N-Nitrosodimethylamine established by FDA following the ongoing investigation which reported carcinogenic impurity in the drug at low levels.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/33i5N9u
via IFTTT